Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism
Lily R. Aleksandrova, Anthony G. Phillips, Yu Tian Wang
Journal of Psychiatry and Neuroscience (2017) Vol. 42, Iss. 4, pp. 222-229
Open Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

Dendritic structural plasticity and neuropsychiatric disease
Marc P. Forrest, Euan Parnell, Peter Penzes
Nature reviews. Neuroscience (2018) Vol. 19, Iss. 4, pp. 215-234
Open Access | Times Cited: 423
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji, Gustavo Vázquez, Carlos A. Zarate
Journal of Affective Disorders (2020) Vol. 278, pp. 542-555
Open Access | Times Cited: 299
Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications
Alexandria Tartt, Madeline Mariani, René Hen, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 6, pp. 2689-2699
Open Access | Times Cited: 229
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Danilo De Gregorio, Argel Aguilar‐Valles, Katrin H. Preller, et al.
Journal of Neuroscience (2020) Vol. 41, Iss. 5, pp. 891-900
Open Access | Times Cited: 186
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 171
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 166
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 164
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
Giovanni Martinotti, Antonio Vita, Andrea Fagiolini, et al.
Journal of Affective Disorders (2022) Vol. 319, pp. 646-654
Closed Access | Times Cited: 72
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder
Andrew J. Cutler, Gregory W. Mattingly, Vladimir Maletic
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 60
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
The Nucleus Accumbens: A Common Target in the Comorbidity of Depression and Addiction
Le Xu, Jun Nan, Yan Lan
Frontiers in Neural Circuits (2020) Vol. 14
Open Access | Times Cited: 85
Depression: Biological markers and treatment
Gordana Nedić Erjavec, Marina Šagud, Matea Nikolac Perković, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110139-110139
Closed Access | Times Cited: 85
Evaluation of the Wistar-Kyoto rat model of depression and the role of synaptic plasticity in depression and antidepressant response
Lily R. Aleksandrova, Yu Tian Wang, Anthony G. Phillips
Neuroscience & Biobehavioral Reviews (2019) Vol. 105, pp. 1-23
Closed Access | Times Cited: 82
Novel drug developmental strategies for treatment‐resistant depression
Éva Borbély, Mária Simon, Eberhard Fuchs, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 6, pp. 1146-1186
Open Access | Times Cited: 69
The molecular pathophysiology of depression and the new therapeutics
Haihua Tian, Zhenyu Hu, Jia Xu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 66
Perspectives for therapy of treatment‐resistant depression
Mariusz Papp, Wiesław Jerzy Cubała, Łukasz Świȩcicki, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 17, pp. 4181-4200
Open Access | Times Cited: 61
Ketamine decreases neuronally released glutamate via retrograde stimulation of presynaptic adenosine A1 receptors
Vesna Lazarevic, Yunting Yang, Ivana Flais, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 12, pp. 7425-7435
Open Access | Times Cited: 56
Ketamine activates adult-born immature granule neurons to rapidly alleviate depression-like behaviors in mice
Radhika Rawat, Elif Tunc‐Ozcan, Tammy L. McGuire, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 51
Targeting inflammation: a potential approach for the treatment of depression
Shvetank Bhatt, Thangaraj Devadoss, Niraj Kumar Jha, et al.
Metabolic Brain Disease (2022) Vol. 38, Iss. 1, pp. 45-59
Closed Access | Times Cited: 49
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
Anees Bahji, Carlos A. Zarate, Gustavo Vázquez
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 6, pp. 853-866
Open Access | Times Cited: 40
Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression
August P. M. Lullau, E. Haga, Eivind Haga Ronold, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 38
Understanding the Biological Relationship between Migraine and Depression
Adrián Viudez‐Martínez, Abraham B. Torregrosa, Francisco Navarrete, et al.
Biomolecules (2024) Vol. 14, Iss. 2, pp. 163-163
Open Access | Times Cited: 9
Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances
Ana Salomé Correia, Nuno Vale
International Journal of Translational Medicine (2024) Vol. 4, Iss. 1, pp. 176-196
Open Access | Times Cited: 8
Inhibition of activated astrocyte ameliorates lipopolysaccharide- induced depressive-like behaviors
Yun Wang, Jing Ni, Lingyan Zhai, et al.
Journal of Affective Disorders (2018) Vol. 242, pp. 52-59
Closed Access | Times Cited: 67
Page 1 - Next Page

Scroll to top